A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

418 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-29

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

NCT01917110

Myopia

COMPLETED NA

Different Microlenses Array for Controlling Myopia Progression in Children and Adolescents

NCT06926556

Myopia Progressing

COMPLETED NA

Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model

NCT05357326

Myopia

UNKNOWN PHASE4

A Clinical Trial to Evaluate the Efficacy and Safety of Defocusing Lenses in Delaying Myopia Progression

NCT06411717

Myopia

RECRUITING NA

3D Designed Defocus Lenses on Myopia Control in Children and Adolescents

NCT07284147

Myopia Progressing

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

The identity of the study eye will be masked to subjects, assessors, and other masked personnel while masking is maintained..

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

Group Type EXPERIMENTAL

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

Intervention Type DEVICE

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Group Type ACTIVE_COMPARATOR

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Intervention Type DEVICE

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

Intervention Type DEVICE

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female aged 8 to 12 years plus 11 months old on the date the Informed Assent and Parental or Guardian Informed Consent are signed and have capacity to provide voluntary informed consent.
2. Subject must meet the following determined by cycloplegic subjective refraction in both eyes at screening:

1. Spherical Equivalent Refractive Error (SERE): between -0.75 D and -4.00 D, inclusive.
2. Astigmatism: ≤ -0.75 D. c. Anisometropia: \< 1.00 D.
3. Subject must be myopic and require lens correction from -0.75 D to -4.00 D, at screening, in each eye.
4. Subject must have distance best-spectacle corrected visual acuity (BSCVA) by non-cycloplegic manifest refraction of +0.04 logMAR (20/20 Snellen equivalent) or better in each eye.
5. Subject and Parent or Guardian must be willing to participate in either the test or the comparator assignment.
6. Subject agrees to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the 24-month study.
7. Subject must have wearable and visually functioning eyeglasses.
8. Subject must be in good general health according to their and parent's or guardian's knowledge

Exclusion Criteria

1. Subject has previously worn, or currently wears rigid gas permeable contact lenses, including orthokeratology lenses.
2. Current or prior use of bifocals, progressive addition lenses, multifocal soft contact lenses, atropine, pirenzepine or ANY other myopia control treatment.
3. Subject appears to exhibit poor personal hygiene (that in the Investigator's opinion might prevent safe contact lens wear).
4. Per oral inquiry from parents/guardian, the subject was born earlier than 30 weeks or weighed less than 1,500 g at birth.
5. Prior strabismus, intraocular, or refractive surgery.
6. Subject using any systemic or local eye medication that interfere with the wearing of corneal contact lenses, pupil size, adjustment or refractive status, or require the removal of lenses during the day".
7. A known allergy to fluorescein, benoxinate, proparacaine, or cyclopentolate.
8. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
9. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
10. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, or diabetes.
11. At the discretion of the Investigator, any ocular, systemic or neuro developmental conditions that could influence refractive development such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis, eyelid hemangiomas, Marfan's syndrome, Down syndrome, Ehlers-Danlos syndrome, Stickler syndrome, ocular albinism, retinopathy of prematurity. Subjects with trichiasis, that in the Investigator's judgement does not interfere with contact lens wear, are eligible for this study.
12. Keratoconus or an irregular cornea.
13. Subjects with any Grade 2 or greater finding during the slit lamp examination, or subjects with any scar or neovascularization within the central 6 mm of the cornea, or subjects with corneal infiltrates, of ANY GRADE.
14. Subjects with any "present" finding during the slit lamp examination (biomicroscopy) that, in the investigator's judgment, interferes with contact lens wear. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment does not interfere with contact lens wear, are eligible for this study.
15. The Investigator for any reason considers that it is not in the best interest of the Subject to participate in the study.
16. Subjects participating in any drug clinical investigation within 4 weeks or device clinical investigation within 2 weeks prior to entry into this study (Screening/Dispensing Visit) and/or planning to do so during the period of study participation.
17. Immediate family or close relative is a member of site study team members

Minimum Eligible Age

8 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.